Statement: Group 1 of the secondary trial has a higher ORR than both the Everolimus + Letrozole cohort of the primary trial and the trastuzumab cohort.
Primary_evidence: Outcome Measurement:    Objective Response Rate (ORR)   Per Response Evaluation Criteria In Solid Tumors (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), at least a 30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.   Time frame: Up to 2 years. Results 1:    Arm/Group Title: NKTR-102 14 Day   Arm/Group Description: NKTR-102: NKTR-102 given on a q14 day schedule   Overall Number of Participants Analyzed: 35   Measure Type: Number   Unit of Measure: percentage of subjects  28.6        (14.6 to 46.3) Results 2:    Arm/Group Title: NKTR-102 21 Days   Arm/Group Description: NKTR-102: NKTR-102 given on a q21 day schedule   Overall Number of Participants Analyzed: 35   Measure Type: Number   Unit of Measure: percentage of subjects  35        (14.6 to 46.3)
Secondary_evidence: Outcome Measurement:    Percentage of Participants With Overall Response Rate (ORR)   Overall Response Rate (ORR) was defined as the proportion of patients whose best overall response was either complete response (CR) or partial response (PR) according to RECIST 1.0 for target lesions and assessed by CT: Complete Response (CR), disappearance of all target lesions for a period of at least one month; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (ORR) = CR + PR. Only descriptive statistics.   Time frame: From the date of randomization until the date of the first documented disease progression or date of death from any cause whichever came first, assessed for approximately 15 months Results 1:    Arm/Group Title: Everolimus + Letrozole   Arm/Group Description: All patients received 2 tablets (5 mg each) of Everolimus (a total of 10 mg) + 1 tablet of Letrozole (2.5 mg) daily until disease progression or as described in the protocol.   Overall Number of Participants Analyzed: 43   Measure Type: Number   Unit of Measure: Percentage of Participants  37.2